Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 May 17;30(5):5135-5144.
doi: 10.3390/curroncol30050388.

PD-L1 Expression in Cutaneous Angiosarcomas: A Systematic Review with Meta-Analysis

Renato Lobrano  1 , Panagiotis Paliogiannis  1   2 , Angelo Zinellu  3 , Giuseppe Palmieri  3   4 , Ivana Persico  4 , Arduino A Mangoni  5   6 , Antonio Cossu  1   2
Affiliations
Meta-Analysis

PD-L1 Expression in Cutaneous Angiosarcomas: A Systematic Review with Meta-Analysis

Renato Lobrano et al. Curr Oncol. .

Abstract

Cutaneous angiosarcoma (CAS) is the most common type of angiosarcoma that predominantly affects older Caucasians. The outcomes of immunotherapy in CAS are currently under investigation in relation to the expression of programmed death ligand 1 (PD-L1) and other biomarkers. We performed a systematic review and metanalysis of data from the current literature reporting on PD-L1 immunohistochemistry expression. A systematic search of publications in the electronic databases PubMed, Web of Science, and Scopus was conducted using the following terms: "PD-L1" and "angiosarcomas". A total of ten studies reporting on 279 cases were identified and included in the meta-analysis. The pooled prevalence of PD-L1 expression in CAS was 54% (95% CI 36-71%), with high heterogeneity (I2 = 84.81%, p < 0.001). In sub-group analysis, the proportion of PD-L1 expression in CAS was significantly (p = 0.049) lower in Asian studies (ES = 35%, 95% CI 28-42%, I2 = 0.0%, p = 0.46) than in European studies (ES = 71%, 95% CI 51-89%, I2 = 48.91%, p = 0.12).

Keywords: PD-L1; cancer; cutaneous angiosarcomas; immunohistochemistry; immunotherapy; skin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flowchart depicting the study selection process.
Figure 2
Figure 2
Forest plot of studies examining the proportion of PD-L1 expression in CAS. [1,8,10,18,19,20,21,22,23,24].
Figure 3
Figure 3
Sensitivity analysis of the PD-L1 expression frequencies in CAS. For each study, the displayed effect size (hollow circles) corresponds to an overall effect size computed from a meta-analysis excluding that study [1,8,10,18,19,20,21,22,23,24].
Figure 4
Figure 4
Funnel plot of studies investigating PD-L1 expression frequencies in CAS after trimming and filling. Dummy studies and genuine studies are represented by enclosed circles and free circles, respectively.
Figure 5
Figure 5
Meta-regression analysis showing the correlation between effect size and number of recruited patients.
Figure 6
Figure 6
Forest plot of studies examining the proportion of PD-L1 expression in CAS according to the continent where studies were conducted. The p-values were not assessable in very small subgroups [1,8,10,18,19,20,21,22,23,24].
Figure 7
Figure 7
Forest plot of studies examining the proportion of PD-L1 expression in CAS according to cut-off values employed. The p-values were not assessable in very small subgroups [1,8,10,18,19,20,21,22,23,24].
See this image and copyright information in PMC

References

    1. Botti G., Scognamiglio G., Marra L., Pizzolorusso A., Di Bonito M., De Cecio R., Cantile M., De Chiara A. Programmed Death Ligand 1 (PD-L1) expression in primary angiosarcoma. J. Cancer. 2017;8:3166–3172. doi: 10.7150/jca.19060. - DOI - PMC - PubMed
    1. Fujisawa Y., Yoshino K., Fujimura T., Nakamura Y., Okiyama N., Ishitsuka Y., Watanabe R., Fujimoto M. Cutaneous angiosarcoma: The possibility of new treatment options especially for patients with large primary tumor. Front. Oncol. 2018;8:46. doi: 10.3389/fonc.2018.00046. - DOI - PMC - PubMed
    1. Palmieri G., Rozzo C.M., Colombino M., Casula M., Sini M.C., Manca A., Pisano M., Doneddu V., Paliogiannis P., Cossu A. Are molecular alterations linked to genetic instability worth to be included as biomarkers for directing or excluding melanoma patients to immunotherapy? Front. Oncol. 2021;11:666624. doi: 10.3389/fonc.2021.666624. - DOI - PMC - PubMed
    1. Buriolla S., Pelizzari G., Corvaja C., Alberti M., Targato G., Bortolot M., Torresan S., Cortiula F., Fasola G., Follador A. Immunotherapy in NSCLC patients with brain metastases. Int. J. Mol. Sci. 2022;23:7068. doi: 10.3390/ijms23137068. - DOI - PMC - PubMed
    1. Park J.C., Krishnakumar H.N., Saladi S.V. Current and future biomarkers for immune checkpoint inhibitors in head and neck squamous cell carcinoma. Curr. Oncol. 2022;29:4185–4198. doi: 10.3390/curroncol29060334. - DOI - PMC - PubMed

Publication types

LinkOut - more resources